Implanon[®] the single rod contraceptive implant

R.M. Melief

Many preparation that occur after stardusment are estapici in the CREST andy 33% of the failures trave estapic and 50% of the bipolar energilation failures.

Abstrak

Implanon[®] merupakan kontrasepsi implant satu batang dengan panjang 4 cm dan diameter 2 mm. Berisi 68 mg etonogestrel (ENG). Implanon akan melepaskan ENG ke aliran darah 60-70 µg/hari pada 5 minggu pertama, menurun menjadi 35-45 µg/hari pada akhir tahun pertama dan turun lagi menjadi 25-30 µg/hari pada akhir tahun kedua. Efek kontrasepsi utama dengan menekan ovulasi. Karena itu efektivitasnya sangat tinggi. Satu minggu setelah Implanon[®] dicabut tidak ditemukan lagi ENG dalam darah, sehingga kehamilan dapat terjadi setiap saat. Keunggulan lain dari Implanon[®] adalah pemasangan dan pencabutan mudah karena hanya terdiri dari satu batang dan menggunakan inserter sekali pakai.

Abstract

Implanon[®] is a single implant contraceptive method. It contains 68 mg etonogestrel. Etonogestrel (ENG) is released from Implanon[®] at a rate of approximately 60-70 μ g/day during week 5-6, declining to approximately 35-45 μ g at the end of the first year, and approximately 25-30 μ g at the end of the third year. The contraceptive action mainly by ovulation inhibition. That's why until now there is not a single pregnancy observed during Implanon-use. Another advantage of Implanon[®] is that it is using a disposable insertion.

Keywords: Implanon[®], single implant contraceptive.

Clinical research programme

Contraceptive efficacy and tolerability of the Implanon® rod was investigated in an extensive clinical development program. Studies were conducted in 9 European countries, North- and South America and in South East Asia. In comparative studies, an implant system consisting of 6 levonorgestrel (LNG) containing capsules (Norplant®), has been used as the reference product.

The database resulting of this development program contains the observations in about 2,300 women treated for 70,000 cycles with Implanon[®] and of about 800 women treated for over 25,000 cycles with Norplant[®].⁶

Features of Implants

There are various differences between the Implanon[®] and Norplant[®] system. The duration of use of Implanon[®] is 3 years compared to 5 years for Norplant[®]. The type and consequently the dose of progestogen is

Medical Adviser Contraception NV Organon, Oss, The Netherlands different: Implanon[®] contains 68 mg of etonogestrel while Norplant[®] holds 216 mg of levonorgestrel. The single Implanon[®]-rod is supplied in a pre-filled and disposable applicator; the 6 Norplant[®] capsules are inserted with a trocar which is re-used after sterilisation. Consequently time needed for insertion and removal is considerably less for the single-rod system. The Implanon[®]-rod has a diameter of 2 mm, the 6 Norplant capsules are 2.4 mm in diameter. The length of the single Implanon[®]-rod is 40 mm compared to a length of 34 mm for each Norplant[®] capsule. The carrier of the active compounds is ethylenevinylacetate (EVA) with Implanon[®] and silicone with Norplant[®].

Pharmacological profile

Serum levels of ENG increase rapidly in the first four days after insertion and reach a level sufficient for ovulation inhibition within the first day. This level declines in the first year of use after which a steady state is reached.^{1,5,6} During the first two years the ENG serum concentration remains at ovulation inhibiting level. In the 3rd year of use ovulation recurred in less than 5% of users.^{5,6} Contraceptive efficacy is maintained by the additional effect on the cervical mucus which inhibits sperm penetration¹. In Norplant[®] users first ovulations have been observed in the second year.^{5,6}

Ovarian activity

Although ovulation is inhibited effectively, substantial ovarian activity may still be present. This is apparent from almost normal FSH activity and estradiol levels.^{1,5,6}

More follicular activity is observed with Norplant[®] compared to Implanon[®], especially during the first year of use indicated by the development of a larger number of pre-ovulatory follicles.⁶

Return of ovulation

Within one week after Implanon[®] removal ENG serum levels can no longer be detected independent of the time Implanon[®] has been used. This indicates the rapid return of the user's normal fertility.^{1,6}

Contraceptive efficacy

The studies assessing contraceptive efficacy of Implanon[®] included more than 70,000 cycles. No pregnancies were observed in Implanon[®] users resulting in a Pearl Index of 0.6 Documented pregnancy rates with Norplant[®] vary from a Pearl Index of 0.2 in the first year to 1.1 in the fifth year.⁷

Bleeding pattern

The bleeding pattern observed with Implanon[®] is comparable to that seen with other progestogen-only contraceptives.⁶

Tolerability

The most frequently reported side effects during the use of Implanon[®] were headache (13.5%) acne (10.3%) which is balanced by the observation of improvement of this condition in approximately the same percentage users, vaginitis (8.9%) and breast pain (7.6%).⁶

The increase in body weight observed with both methods may be considered only partially attributable to the treatment and is not much different from a normal weight increase over time in women who are not exposed to exogenous sex steroids.⁶

Reported incidences of side effects were higher in the studies performed in USA/Europe and lower in the trials carried out in Indonesia. The above figures represent the combined data.

No statistically significant differences in side effects were reported between Implanon[®] and Norplant[®] us13

ers. No clinically relevant effects on metabolic parameters have been observed during the use of Implanon $^{\textcircled{B},6}$

Beneficial effect on dysmenorrhoea

Implanon clearly demonstrated a beneficial effect on the occurrence or severity of dysmenorrhoea.⁶

Insertion and removal

Insertion and removal of the Implanon[®] rod can be performed four times faster than with the Norplant system. On average Implanon[®] insertion takes 1.1 minutes, while removal requires 2.7 minutes.⁶

Hardly any complications with insertion were reported for either method. A ten-fold difference in removal complications was observed for Norplant[®] (6%) compared to Implanon[®] (0.6%).⁶

Women might change doctors or move to other areas while using Implanon[®]. Therefore Organon recommends to keep the insertion site of Implanon[®] consistent world-wide: 6-8 cm above the elbow at the inner side of the upper arm on the non-dominant side, in the groove between the biceps and triceps (sulcus bicipitalis medialis).

By following this procedure, users can palpate the implant as it is in situ and the removing doctor can easily locate the implant by palpation.

Conclusion

In summary, Implanon[®] offers a compliance independent method for three years of contraceptive protection. The hormonal exposure is low. Physicians can, after being trained, easily insert and remove the single rod. All described features of Implanon[®] contribute to a high acceptability of users and physicians.

References

- Davies GC, Li XF, Newton JR, Beek A van, Coelingh Bennink HJT. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-keto-desogestrel. Contraception 1993; 47: 251-61.
- Geelen JAA, Wardt JTH van der, Voortman G, Maassen GCT, Eenink MJD. Release kinetics of 3-ketodesogestrel from contraceptive implants (Implanon[®]) in dogs: comparison with in-vitro data. Contraception 1993; 47: 215-26.
- Diaz S, Paves M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial with 3-ketodesogestrel implants. Contraception 1991; 44: 393-408.

Med J Indones

14 Melief

plant[®]. Fertil Steril 1998; 69: 714-22.

6. Data on file, 1996, NV Organon, Oss, The Netherlands

 Croxatto H. Norplant[®]: Levonorgestrel-Releasing Contraceptive Implant. Annals Med 1993; 25: 155-60.

More following activity is observed with Morplere⁴⁶ nompared to Impleated⁴⁰, especially during the first year of use indicaved by the development of a larger number of pre-ovalutory follocies/

Referra al avaiation

Within one work after in planning removal ENCI asrun invelation or longer by detacked influencement of the time implance[®] has been used. This automize the could remove of the user's normal famility 1.⁴

Contracting live afforest

The intuities neteroing contraceptive officacy of Implanone included more than 70.000 cycles. No progmercies were observed in Implement mers neithing on a Fearl Judan of 04 Fournanient programsy more with Norphalte vary from a Pourl Indon of 0.2 in the freq year to 1.1 m the fifth year?

Breefing pattern

The biseding pattern observed with Implantm² is comparable to that sees with other programgemently contriceptives.⁴

Tolerability

The most frequently organized side effects during the uses of frequency¹⁰ were headlights (11.5%) mene (10.5%) which is halanced by the observation of improvement of this condition in approximately the same percentage mean variantic (3.9%) and heart one (7.6%).⁹

The increase in body weight observed with both methods may be considered only partially attributable to the resument and is not much different from a corrual weight mercase over time to woman who memory expected to exogenous sex stemats.⁶

Reported incidences of side effects write higher in the inditet performed in USA/Buropa and lower in the tradu sarried out in Indonesia. The above figures tepresent the combined that.

No statistically symilicant dollarations in side uffects were reported between Implantational and Norplant[®] us-

 Lantz A, Nosher JL, Pasquale A, Siegel RL. Ultrasound characteristics of subdermally implanted Implanon[™] contraceptive rods. Contraception 1997; 56: 323-7.

 Mäkäräinen L, Beek A van, Tuomivaara L, Asplund B, Coelingh Bennink HJT. Ovarian function during the use of a single contraceptive implant: Implanon[®] compared with Nor-

Iniplation clauty demonstrated a transform ethem of

Insertion and removal

Interaction and actioned of the (replaced and the forperformed flate titles fracter that with the "organal system. On restricts implation? interaction rates 1.1 minutes, withlic removal equires 2.7 minutes.)

Flority any musplications with insertion were reported for eather method. A reacfold difference to reinoved emoplications was observed for Europiant⁸ (6.33) compared to Implement¹¹ (0.031)⁸

Weman might change doctors or move to other from while using (mplunon® Thurchus Organou recommends to karp the insertion set of Implunon® notatiotent weakd-white 6-8 cm above the offorw in the times slites white upper arm on the isomonanimum sole, in the prome between the heaper and fractps (soleus bleft)mic methality.

By Inflowing this procedure, user-can polyate the implant as it is in interned the removing decrot can easily locate the ampliant by polymetry.

Constructor

In automatic Implement affers a compliance to to produce weshed for three years of contraciplicate protection. The hormonal accounts is low. Physician ran, affec being mained, carely orient and remove the simple real. All detection features of Implement contribute to a black accentrability of users and physiciants.

References

- Janvas GE, Es XJ, Numiton ER, José A vanz-Goellingh Benalex LET. Hitkans: interactionarity, availant activity, and manment islamiling granters with a single scontenengity (10(1)).
 Interaction of the optimizer. Continuumption (1002), 47 (21)–61.
- Oceans FAA, Wardt JTH van der, Warmann G, Munsen ULT, Isamak MED, Kalause Invense of A-kalarieurgentrei from constructive Implement (Implementer in deps. contract) sam with an etime data. Communiquint 1993; 10:315–35.
- Black Physics R. Mark Young AJ, Bardin CW, Churnell HP, Clinical and with Introdesignated implement Churrenterfore 19912, vol. 2019, arXiv